Revenue from Contracts with Customers Revenue from Contracts with Customers (Notes)

9 Months Ended

Sep. 27, 2024

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

4. Revenue from Contracts with Customers

Product Sales Revenue

See Note 15 for presentation of the Company's net sales by product family.

Reserves for variable consideration

The following table reflects activity in the Company's sales reserve accounts:

	Rebates and Chargebacks (1)		Product Returns		Other Sales Deductions		Total
Balance as of December 30, 2022 (Predecessor)	$	265.3	$	16.0	$	12.7	$	294.0
Provisions	1,150.5		8.5		36.1		1,195.1
Payments or credits	(1,185.1)		(11.2)		(36.0)		(1,232.3)
Balance as of September 29, 2023 (Predecessor)	$	230.7	$	13.3	$	12.8	$	256.8
Balance as of December 29, 2023 (Successor)	$	201.6	$	14.5	$	11.3	$	227.4
Provisions	1,206.2		15.9		43.6		1,265.7
Payments or credits	(1,206.9)		(15.8)		(34.9)		(1,257.6)
Balance as of September 27, 2024 (Successor)	$	200.9	$	14.6	$	20.0	$	235.5

(1)Includes $29.6 million and $59.0 million of accrued Medicaid and $33.8 million and $35.1 million of accrued rebates as of September 27, 2024 (Successor) and December 29, 2023 (Successor), respectively, included within accrued and other current liabilities in the unaudited condensed consolidated balance sheets.

Product sales transferred to customers at a point in time and over time were as follows:

	Successor		Predecessor
	Three Months Ended September 27, 2024		Three Months Ended September 29, 2023
Product sales transferred at a point in time	87.1	%	85.1	%
Product sales transferred over time	12.9		14.9

	Successor		Predecessor
	Nine Months Ended September 27, 2024		Nine Months Ended September 29, 2023
Product sales transferred at a point in time	86.2	%	83.1	%
Product sales transferred over time	13.8		16.9

Transaction price allocated to the remaining performance obligations

The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of September 27, 2024 (Successor):

Remainder of Fiscal 2024	$	21.8
Fiscal 2025	78.1
Fiscal 2026	49.3
Thereafter	18.9